Neoadjuvant versus adjuvant chemoradiotherapy for resectable cT3‐4a esophageal squamous cell carcinoma: A matched cohort analysis Authors: Mingqiang Lin, Yilin Yu, Yibing Hu, Rong Zheng, Jiancheng Li, Qiwei Yao Published: 2026 ABSTRACT AbstractBackgroundThe optimal management of locally advanced resectable esophageal squamous cell carcinoma (ESCC), particularly for cT3‐4a disease, remains debated. This study aimed to compare the survival outcomes and toxicity profiles of neoadjuvant chemoradiotherapy (NCRT) and adjuvant chemoradiotherapy (ACRT) in this patient population.MethodsWe retrospectively analyzed 223 patients with resectable cT3‐4a ESCC who underwent radical surgery combined with NCRT or ACRT. Propensity score matching (PSM) was used to generate 59 balanced pairs for comparative analysis.ResultsAfter matching, the NCRT group demonstrated significantly improved overall survival (OS) compared with the ACRT group, with a median OS of 62 versus 46 months and 5‐year OS rates of 66.6% versus 47.5%, respectively (p = 0.023). Despite the longer median progression‐free survival (PFS) observed in the NCRT group (53 vs. 42 months), the difference in the 5‐year PFS rate was not statistically significant (56.7% vs. 44.4%; p = 0.113). Furthermore, the two groups exhibited similar profiles of treatment‐related adverse events (all p > 0.05). Multivariable analysis identified treatment strategy, body mass index (BMI), and clinical nodal (cN) status as independent predictors of OS (all p < 0.01). A novel prognostic score (PS) integrating BMI and cN status effectively stratified patients into distinct risk categories, with higher scores predicting poorer prognosis but not in the neoadjuvant subgroup.ConclusionsFor patients with resectable cT3‐4a ESCC, NCRT provides superior OS compared to ACRT, with similar PFS and toxicity. These findings support the prioritization of NCRT for this disease stage; however, larger randomized trials are warranted to optimize patient selection. INTRODUCTION According to recent global cancer statistics, esophageal cancer ranks 11th in incidence and 6th in mortality worldwide. 1 In China, esophageal squamous cell carcinoma (ESCC) accounts for approximately 90% of all esophageal cancer cases. 2 Despite advances in diagnosis and treatment, the 5‐year survival rate of patients with ESCC remains persistently low. 3 Surgery is the cornerstone of treatment; however, even after radical resection, the median survival rarely exceeds 23 months owing to frequent residual tumor foci. 4 , 5 Evidence from pivotal trials supports neoadjuvant chemoradiotherapy (NCRT) followed by esophagectomy as the standard management for locally advanced esophageal cancer. The CROSS trial demonstrated significant survival benefits, although its cohort predominantly comprised adenocarcinoma. 6 The NEOCRTEC5010 trial subsequently validated this strategy specifically for ESCC. 7 Despite this standard, NCRT implementation in China faces barriers, with many patients opting for initial surgery. Adjuvant chemoradiotherapy (ACRT) may also offer survival benefits. 8 , 9 , 10 However, direct comparisons of NCRT and ACRT are scarce and inconsistent. 11 , 12 , 13 , 14 Notably, most patients enrolled in these comparative studies had clinically advanced (cT3‐4a) disease. In fact, over half of ESCC patients present with tumors extending beyond the esophageal wall at diagnosis. This cT3‐4a subgroup is characterized by extensive local invasion and elevated micrometastatic risk, yet remains technically resectable. 15 Compared with patients with earlier‐stage (cT1‐2) disease, these patients experience a significantly poorer prognosis following combined modality treatment. 8 , 16 Therefore, this study aimed to compare survival outcomes and treatment‐related toxicities between NCRT and ACRT, specifically in resectable cT3‐4a ESCC patients, to provide high‐level evidence to guide clinical management for this distinct high‐risk cohort. METHODS Patient characteristics This retrospective analysis included patients with initially diagnosed cT3‐4aNanyM0 ESCC treated at Fujian Cancer Hospital between January 2006 and September 2017. All patients had histologically confirmed ESCC without any evidence of distant metastasis. Each patient underwent radical esophagectomy combined with NCRT or ACRT. Patient demographics and treatment‐related toxicity data were extracted from the medical records. Tumor staging was performed according to the American Joint Committee on Cancer (AJCC) 8th edition TNM criteria. This study was approved by the Ethics Committee of Fujian Provincial Cancer Hospital (No. K2022‐007‐01). Chemoradiotherapy Patients received either NCRT or ACRT, with all radiotherapy delivered via a medical linear accelerator using a 6 MV photon beam for intensity‐modulated radiotherapy (IMRT). In the NCRT group, the gross tumor volume (GTV) encompassed all macroscopic disease, incorporating the primary esophageal lesion and radiologically positive lymph nodes. The clinical target volume (CTV) was defined by extending the GTV by 3 cm craniocaudally and 0.5–1.0 cm radially to cover regions at risk for subclinical disease. The planning target volume (PTV) incorporated a 0.5 cm expansion around the CTV, which received 41.4‐50 Gy of radiation administered at daily doses of 1.8–2.0 Gy over a 5‐day week. In the ACRT group, the CTV covered the postoperative tumor bed, anastomotic, and high‐risk lymphatic regions. Similarly, the PTV was generated by uniformly expanding the CTV by 0.5 cm. A total dose of 50 Gy was delivered in 25 fractions by conventional fractionation. Both groups received concurrent platinum‐based doublet chemotherapy with radiotherapy and completed at least two cycles. Surgery The NCRT group underwent esophagectomy 4–6 weeks after chemoradiotherapy, while the ACRT group started adjuvant treatment within 8 weeks after surgery. All patients underwent uniform preoperative staging for resectability, followed by esophagectomy with two‐ or three‐field lymphadenectomy. Follow‐up Follow‐ups were conducted on a predefined schedule: quarterly in years 1–2, semi‐annually in years 3–5, and annually thereafter. Each assessment comprised physical examination, laboratory blood tests, thoracoabdominal computed tomography, and esophageal radiography. Selected patients additionally underwent emission computed tomography or positron emission tomography. This study focused on overall survival (OS) and progression‐free survival (PFS) as the primary endpoints. The Version 4.0 National Cancer Institute Common Terminology Criteria for Adverse Events (NCI CTCAE) was used to grade treatment‐related toxicities. Statistical analysis Appropriate statistical tests were employed to compare intergroup baseline characteristics: continuous variables through independent t‐tests or ANOVA and categorical variables via Pearson's chi‐square or Fisher's exact test. A propensity score matching (PSM) approach was implemented to mitigate confounding. Scores were generated from logistic regression and matched using nearest‐neighbor matching (caliper = 0.03). Survival outcomes were analyzed by Kaplan–Meier method with log‐rank tests, followed by Cox proportional hazards regression, which incorporated significant univariate variables (p < 0.05) to construct the multivariate model. A prognostic nomogram was developed using the rms package in R based on multivariate results. All analyses were performed using SPSS 24.0 and R software 4.0.2, with a significance threshold of p < 0.05. RESULTS Patient characteristics The original cohort for PSM comprised 223 patients. As summarized in Table 1, the cohort consisted of 190 males (85.2%) and 33 females (14.8%) with an overall median age of 60 years (range: 39–75). Among them, 106 (47.5%) received NCRT, and 117 (52.5%) underwent ACRT. Prior to matching, the two groups exhibited significant disparities in smoking history (p = 0.007) and clinical nodal (cN) status (p < 0.001). After PSM using a 1:1 ratio, a balanced cohort of 59 patients per group was generated, which yielded comparable baseline characteristics between the NCRT and ACRT groups. TABLE 1Baseline characteristics in the NCRT and ACRT groups before and after PSM.Before PSM [N = 223]After PSM [N = 118]Characteristics NCRT [N = 106] (%) ACRT [N = 117] (%) p NCRT [N = 59] (%) ACRT [N = 59] (%) p Sex0.0770.470Male95 (89.6)95 (81.2)50 (84.7)47 (79.7)Female11 (10.4)22 (18.8)9 (15.3)12 (20.3)Age (years)0.8890.552< 6068 (64.2)74 (63.2)42 (71.2)39 (66.1)≥ 6038 (35.8)43 (36.8)17 (28.8)20 (33.9)Hypertension0.2930.542No86 (81.1)101 (86.3)54 (91.5)52 (88.1)Yes20 (18.9)16 (13.7)5 (8.5)7 (11.9)Diabetes0.6421.000No97 (91.5)109 (93.2)56 (94.9)56 (94.9)Yes9 (8.5)8 (6.8)3 (5.1)3 (5.1)Smoking0.0070.851No49 (46.2)75 (64.1)35 (59.3)36 (61.0)Yes57 (53.8)42 (35.9)24 (40.7)23 (39.0)BMI (kg/m2)0.6510.706< 21.763 (59.4)73 (62.4)35 (59.3)37 (62.7)≥ 21.743 (40.6)44 (37.6)24 (40.7)22 (37.3)cT0.0981.000T372 (67.9)91 (77.8)47 (79.7)47 (79.7)T434 (32.1)26 (22.2)12 (20.3)12 (20.3)cN< 0.0011.000N020 (18.9)73 (62.4)17 (28.8)17 (28.8)N+86 (81.1)44 (37.6)42 (71.2)42 (71.2)Tumor length (cm)0.4991.000< 630 (28.3)38 (32.5)18 (30.5)18 (30.5)≥ 676 (71.7)79 (67.5)41 (69.5)41 (69.5)Abbreviations: ACRT, adjuvant chemoradiotherapy; BMI, body mass index; cN, clinical nodal status; cT, clinical T stage; NRCT, neoadjuvant chemoradiotherapy; PSM, propensity score matching.John Wiley & Sons, Ltd. Baseline characteristics in the NCRT and ACRT groups before and after PSM. NCRT [N = 106] (%) ACRT [N = 117] (%) NCRT [N = 59] (%) ACRT [N = 59] (%) Abbreviations: ACRT, adjuvant chemoradiotherapy; BMI, body mass index; cN, clinical nodal status; cT, clinical T stage; NRCT, neoadjuvant chemoradiotherapy; PSM, propensity score matching. Survival outcomes From the initial cohort of 223 patients before PSM, 114 (51.1%) survived to the final follow‐up. The median OS for the entire cohort was 53 months, with 1‐, 3‐, and 5‑year OS rates of 86.5%, 64.1%, and 55.3%, respectively. The median OS was 53 months in the NCRT group and 49 months in the ACRT group, with 1‐, 3‐, and 5‑year OS rates of 84.9% vs. 88.0%, 63.2% vs. 64.9%, and 56.4% vs. 54.4%, respectively. The median PFS for the entire cohort was 42 months, with 1‐, 3‐, and 5‑year PFS rates of 76.2%, 55.6%, and 49.5%, respectively. The median PFS was 38 months in the NCRT group and 48 months in the ACRT group, with 1‐, 3‐, and 5‑year PFS rates of 76.4% vs. 76.1%, 52.8% vs. 58.1%, and 47.5% vs. 51.3%, respectively. Kaplan–Meier curves for OS and PFS before matching are shown in Fig. 1A–B. Log‐rank tests indicated comparable outcomes in OS (hazard ratio [HR] = 0.99; 95% confidence interval [CI]: 0.68–1.45; p = 0.976) and PFS (HR = 0.89; 95% CI: 0.62–1.27; p = 0.514) between the two groups before matching. Kaplan–Meier curves comparing OS and PFS between the NCRT and ACRT groups before and after PSM. (A) OS before PSM; (B) PFS before PSM; (C) OS after PSM; and (D) PFS after PSM. ACRT, adjuvant chemoradiotherapy; PSM, propensity score matching; OS, overall survival; PFS, progression‐free survival; NCRT, neoadjuvant chemoradiotherapy After PSM, 61 patients (51.7%) were alive at the final follow‐up. The median OS in the matched cohort was 56.5 months, with 1‐, 3‐, and 5‑year OS rates of 89.0%, 66.9%, and 57.0%, respectively. Patients receiving NCRT demonstrated a superior median OS relative to those receiving ACRT (62 vs. 46 months), with 1‐, 3‐, and 5‑year OS rates of 89.8% vs. 88.1%, 74.6% vs. 59.3%, and 66.6% vs. 47.5%, respectively. In the matched cohort, the median PFS was 46.5 months. The 1‐, 3‐, and 5‑year PFS rates were 78.8%, 57.6%, and 50.6%, respectively. The NCRT group had a longer median PFS than the ACRT group (53 vs. 42 months), with 1‐, 3‐, and 5‑year PFS rates of 84.7% vs. 72.9%, 64.4% vs. 50.8%, and 56.7% vs. 44.4%, respectively. Following matching, the NCRT group showed significantly improved OS (HR = 1.86, 95% CI: 1.09‐3.18, p = 0.023) but comparable PFS (HR = 1.50, 95% CI: 0.91‐2.49, p = 0.113) versus the ACRT group, as depicted in the Kaplan–Meier curves (Fig. 1C–D). A summary of the median OS and PFS values with corresponding p‐values before and after matching is provided in Table 2. TABLE 2Median OS and PFS of the NCRT and ACRT groups before and after propensity score matching.Before PSM [N = 223]After PSM [N = 118]Outcome NCRT [N = 106] (%) ACRT [N = 117] (%) p NCRT [N = 59] (%) ACRT [N = 59] (%) p OS, median (months)53490.97662460.023PFS, median (months)38480.51453420.113Abbreviations: ACRT, adjuvant chemoradiotherapy; NRCT, neoadjuvant chemoradiotherapy; OS, overall survival; PFS, progression‐free survival; PSM, propensity score matching.John Wiley & Sons, Ltd. Median OS and PFS of the NCRT and ACRT groups before and after propensity score matching. NCRT [N = 106] (%) ACRT [N = 117] (%) NCRT [N = 59] (%) ACRT [N = 59] (%) Abbreviations: ACRT, adjuvant chemoradiotherapy; NRCT, neoadjuvant chemoradiotherapy; OS, overall survival; PFS, progression‐free survival; PSM, propensity score matching. The prognostic factors for OS identified by univariate and multivariate Cox regression after matching are summarized in Table 3. In the univariate analysis, factors including sex, age, hypertension, diabetes, smoking, body mass index (BMI), cT status, cN status, tumor length, and treatment group were incorporated. Variables that showed a significant association with OS in the univariate analysis (BMI: HR = 1.84, p = 0.022; cN status: HR = 0.43, p = 0.015; and treatment: HR = 0.54, p = 0.024) were then entered into the multivariate model, in which all three remained independent predictors (BMI: HR = 2.05, p = 0.008; cN status: HR = 0.39, p = 0.007; and treatment: HR = 0.47, p = 0.007). TABLE 3Prognostic factors for OS in the PSM cohort: univariate and multivariate Cox analyses.CharacteristicsUnivariate AnalysisMultivariate AnalysisHR95% CI p HR95% CI p SexMale vs. Female1.250.61‐2.540.545Age (years)<60 vs. ≥600.840.48‐1.470.535HypertensionNo vs. Yes0.940.40–2.190.881DiabetesNo vs. Yes0.480.17–1.320.155SmokingNo vs. Yes1.400.81–2.420.228BMI (kg/m2)<21.7 vs. ≥21.71.841.09‐3.100.0222.051.21‐3.470.008cTT3 vs. T40.970.50‐1.880.936cNN0 vs. N+0.430.22‐0.850.0150.390.20‐0.780.007Tumor length (cm)<6 vs. ≥61.090.63‐1.900.752GroupNCRT vs. ACRT0.540.32‐0.920.0240.470.27‐0.810.007Abbreviations: ACRT, adjuvant chemoradiotherapy; BMI, body mass index; CI, confidence interval; cN, clinical nodal status; cT, clinical T stage; HR, hazard ratio; NRCT, neoadjuvant chemoradiotherapy; OS, overall survival; PSM, propensity score matching.John Wiley & Sons, Ltd. Prognostic factors for OS in the PSM cohort: univariate and multivariate Cox analyses. Abbreviations: ACRT, adjuvant chemoradiotherapy; BMI, body mass index; CI, confidence interval; cN, clinical nodal status; cT, clinical T stage; HR, hazard ratio; NRCT, neoadjuvant chemoradiotherapy; OS, overall survival; PSM, propensity score matching. Prognostic model construction We developed a prognostic nomogram incorporating BMI, cN status, and treatment group to predict the probability of individual OS (Fig. 2A). The nomogram had a concordance index (C‐index) of 0.66 for OS prediction. For 1‐, 3‐, and 5‑year OS, calibration plots indicated strong concordance between the model predictions and the observed survival (Fig. 2B–D), indicating satisfactory performance of the model. Nomogram and calibration curves for predicting OS probability in 118 ESCC patients. (A) Nomogram integrating BMI, cN status, and treatment strategy. (B) Calibration curve for 1‐year OS; (C) Calibration curve for 3‐year OS; (D) Calibration curve for 5‐year OS. BMI, body mass index; cN status, clinical nodal status; ESCC, esophageal squamous cell carcinoma; OS, overall survival. Prognostic score and risk stratification We further developed a novel PS that integrated BMI and cN status. Patients were assigned scores as follows: 3 points for the coexistence of low BMI (< 21.7 kg/m2) and node‐positive (N+) disease, 2 points for either low BMI or N+ status alone, and 1 point for the absence of both risk factors. Using this scoring system, a three‐tier risk classification was applied to the patients: high‐ (PS 3), intermediate‐ (PS 2), and low‐risk (PS 1). The median OS progressively increased with decreasing risk, and median OS durations of 35, 59, and 71 months were recorded, corresponding to the high‐, intermediate‐, and low‐risk categories, respectively. The corresponding 1‐year OS rates were 72.7%, 93.8%, and 100.0% for the high‐, intermediate‐, and low‐risk groups, respectively; the 3‐year OS rates were 48.5%, 70.3%, and 85.7%; and the 5‐year OS rates were 37.7%, 59.8%, and 80.0%. As shown in Fig. 3, the PS effectively stratified OS outcomes in the overall population (Fig. 3A) and the ACRT subgroup (Fig. 3C), with patients in the highest risk category (PS 3) exhibiting significantly worse survival than those in PS 1 (p = 0.002 for both cohorts) and PS 2 (overall: p = 0.015; ACRT: p = 0.005). However, no significant survival differences were observed between any of the risk groups in the NCRT subgroup (Fig. 3B: PS 1 vs. 2, p = 0.365; PS 1 vs. 3, p = 0.124; PS 2 vs. 3, p = 0.172). Kaplan–Meier curves comparing OS between different risk‐stratification groups defined by the PS. (A) OS by risk groups in the entire cohort; (B) OS by risk groups in the NCRT subgroup; (C) OS by risk groups in the ACRT subgroup. ACRT, adjuvant chemoradiotherapy; NCRT, neoadjuvant chemoradiotherapy; OS, overall survival; PS, prognostic score. Postoperative histopathological characteristics Table 4 details the postoperative histopathological characteristics of the cohort both before and after matching. Both prior to and following matching, the NCRT and ACRT groups consistently differed in pT/ypT stage, pN/ypN status, lymphovascular invasion, and the number of positive lymph nodes. These differences became more statistically significant following matching (all p < 0.001). TABLE 4Postoperative histopathological characteristics in the NCRT and ACRT groups before and after PSM.Before PSM [N = 223]After PSM [N = 118]Histopathological characteristics NCRT [N = 106] (%) ACRT [N = 117] (%) p NCRT [N = 59] (%) ACRT [N = 59] (%) p pT (ypT)< 0.001< 0.001T369 (65.1)8 (6.8)45 (76.3)4 (6.8)T437 (34.9)109 (93.2)14 (23.7)55 (93.2)pN (ypN)< 0.001< 0.001N063 (59.4)28 (23.9)38 (64.4)11 (18.6)N+43 (40.6)89 (76.1)21 (35.6)48 (81.4)Lymphovascular invasion0.0010.001No90 (84.9)77 (65.8)54 (91.5)39 (66.1)Yes16 (15.1)40 (34.2)5 (8.5)20 (33.9)Nerve invasion0.7320.113No94 (88.7)102 (87.2)56 (94.9)51 (86.4)Yes12 (11.3)15 (12.8)3 (5.1)8 (13.6)No. of positive lymph nodes1.35 ± 3.212.21 ± 2.140.0190.93 ± 1.912.63 ± 2.39< 0.001Abbreviations: ACRT, adjuvant chemoradiotherapy; NRCT, neoadjuvant chemoradiotherapy; pN, pathological nodal status; PSM, propensity score matching; pT, pathologic T stage; ypN, post‐neoadjuvant therapy pathologic nodal status; ypT, post‐neoadjuvant therapy pathologic T stage.John Wiley & Sons, Ltd. Postoperative histopathological characteristics in the NCRT and ACRT groups before and after PSM. NCRT [N = 106] (%) ACRT [N = 117] (%) NCRT [N = 59] (%) ACRT [N = 59] (%) Abbreviations: ACRT, adjuvant chemoradiotherapy; NRCT, neoadjuvant chemoradiotherapy; pN, pathological nodal status; PSM, propensity score matching; pT, pathologic T stage; ypN, post‐neoadjuvant therapy pathologic nodal status; ypT, post‐neoadjuvant therapy pathologic T stage. Treatment‐related adverse events The profiles of the treatment‐related adverse events before and after PSM are shown in Table 5. Before matching, the rates of anastomotic leakage differed significantly between the two treatment arms (p = 0.047). After matching, however, the two groups showed comparable rates of major postoperative morbidity encompassing anastomotic leakage, intra‐abdominal bleeding, pneumonia, respiratory insufficiency, and grade ≥3 myelosuppression (all p > 0.05). Notably, one case of mortality due to intra‐abdominal hemorrhage at 90 days postoperatively was recorded in the NCRT group. TABLE 5Treatment‐related adverse events in NCRT versus ACRT groups before and after PSM.Before PSM [N = 223]After PSM [N = 118]Characteristic NCRT [N = 106] (%) ACRT [N = 117] (%) p NCRT [N = 59] (%) ACRT [N = 59] (%) p Anastomotic leakage0.0470.223No90 (84.9)109 (93.2)51 (86.4)55 (93.2)Yes16 (15.1)8 (6.8)8 (13.6)4 (6.8)Pneumonia0.4540.850No60 (56.6)72 (61.5)36 (61.0)37 (62.7)Yes46 (43.4)45 (38.5)23 (39.0)22 (37.3)Respiratory failure0.4751.000No105 (99.1)117 (100)58 (98.3)59 (100)Yes1 (0.9)0 (0)1 (1.7)0 (0)Intra‐abdominal bleeding0.6061.000No104 (98.1)116 (99.1)58 (98.3)59 (100)Yes2 (1.9)1 (0.9)1 (1.7)0 (0)Death ≤ 90 days0.4751.000No105 (99.1)117 (100)59 (100)59 (100)Yes1 (0.9)0 (0)0 (0)0 (0)≥ Grade 3 myelosuppression0.1990.694No79 (74.5)78 (66.7)41 (69.5)39 (66.1)Yes27 (25.5)39 (33.3)18 (30.5)20 (33.9)Abbreviations: ACRT, adjuvant chemoradiotherapy; NRCT, neoadjuvant chemoradiotherapy; PSM, propensity score matching.John Wiley & Sons, Ltd. Treatment‐related adverse events in NCRT versus ACRT groups before and after PSM. NCRT [N = 106] (%) ACRT [N = 117] (%) NCRT [N = 59] (%) ACRT [N = 59] (%) Abbreviations: ACRT, adjuvant chemoradiotherapy; NRCT, neoadjuvant chemoradiotherapy; PSM, propensity score matching. DISCUSSION ESCC continues to pose a significant therapeutic challenge, as the 5‐year survival rate has not substantially improved beyond 20% despite evolving treatment approaches. 17 Surgical resection serves as the cornerstone in the management of resectable ESCC; however, approximately 50% of patients experience local recurrence following surgery. 18 Chemoradiotherapy plays an essential role in the comprehensive management of locally advanced resectable ESCC. 3 The optimal sequence of chemoradiotherapy, either before or after surgery, remains undetermined, despite both NCRT and ACRT showing superior survival outcomes compared to surgery alone. Previous studies on multimodal treatment strategies for locally advanced resectable ESCC have commonly included patients with clinical stages cT3‐4a or cN+. 19 , 20 Among these, cT3‐4a tumors constitute a distinct high‐risk subgroup characterized by extensive local invasion, high frequency of lymph node metastasis and micrometastatic dissemination, and poor outcomes with surgery alone. 15 , 21 , 22 This population has consistently been associated with an unfavorable prognosis and constitutes a critical target for intensive multimodal therapy. To improve cohort homogeneity and allow for a more precise evaluation of treatment strategies in this high‐risk subgroup, we specifically focused on resectable cT3‐4a ESCC patients. PSM was employed to improve the comparability between patients receiving NCRT and those undergoing ACRT. After matching, despite comparable PFS and adverse event profiles, a significant OS disparity was observed between the NCRT and ACRT strategies. Evidence from the CROSS trial (n = 366), a landmark study on resectable locally advanced esophageal/esophagogastric junction cancer, demonstrated significant OS improvement with NCRT plus surgery, corroborating its benefit over surgery alone. 6 However, only 23% of the enrolled patients in this trial had squamous cell carcinoma, which may limit the generalizability of these findings to ESCC patients. The phase III multicenter NEOCRTEC5010 trial in China, which specifically targeted ESCC, enrolled 451 patients with potentially resectable thoracic ESCC. 7 The results demonstrated that NCRT significantly improved the median OS (100.1 vs. 66.5 months) and PFS (100.1 vs. 41.7 months) compared to surgery alone. The median OS in the NCRT group was 53 months in the unmatched cohort and 62 months after PSM in our study, which was lower than that reported in the NEOCRTEC5010 trial. This discrepancy may be attributed to several factors, including fundamental differences between real‐world observational studies and randomized controlled trials, variations in inclusion criteria between the studies, and the specific composition of the patient populations. Notably, the NEOCRTEC5010 trial included 36 patients (16%) with clinically staged T1‐2 disease, who were excluded from our study, which focused exclusively on cT3‐4a ESCC patients. However, in real‐world Chinese practice, the adoption of NCRT for locally advanced resectable ESCC remains limited, owing to factors such as patient preference and challenges in multidisciplinary collaboration. Consequently, adjuvant therapies continue to be widely utilized in the management of locally advanced ESCC, with multiple studies confirming their substantial survival benefit, comparable to NCRT. Compared to surgery alone, ACRT has been shown to improve OS while reducing the rates of metastasis and recurrence. 8 , 9 , 10 A propensity‐matched analysis by Hwang et al. highlighted the survival advantage of ACRT, particularly in ESCC patients with high‐risk characteristics such as pT3/4 stage, N+ status, poor differentiation, and R1/R2 resections. Chen et al. reported that adding chemotherapy to radiotherapy significantly improved OS compared to radiotherapy alone (53.5 vs. 41.7 months, p = 0.030). 23 In our study, the median OS in the ACRT group was 49 months in the pre‐matched cohort and 46 months after PSM, results that are consistent with the 53.5‐month median OS reported by Chen et al. in their postoperative chemoradiotherapy group. The principal advantage of ACRT is its ability to achieve precise pathological staging immediately after surgery, enabling personalized subsequent treatment planning. In contrast, NCRT offers benefits such as eradication of systemic micrometastases, tumor downstaging, higher R0 resection rates, and improved patient survival. 12 Although both approaches have demonstrated efficacy, direct comparative evidence regarding the optimal sequencing strategies for chemoradiotherapy combined with surgery in locally advanced resectable ESCC remains limited. 12 , 13 , 14 To our knowledge, our study represents the first comparative analysis directly evaluating the survival outcomes of NCRT versus ACRT, specifically in resectable cT3‐4a ESCC patients. Our analysis demonstrated no significant differences in PFS or OS between the treatment groups before matching. However, after PSM, the NCRT group showed significantly superior OS outcomes compared with the ACRT group, while maintaining comparable PFS. Additionally, the NCRT approach induced a substantial pathological response, with over 50% of patients achieving significant tumor regression. Evidence from a meta‐analysis by Xiao et al. showed a significant OS benefit with neoadjuvant therapy (HR = 0.88; 95% CI: 0.79–0.98) and higher R0 resection rates, but also with increased perioperative mortality following esophagectomy. 24 These elevated risks may be attributed to NCRT‐related toxicities including myelosuppression, hepatic and renal impairment, systemic inflammation, nutritional depletion, and surgical field fibrosis. Notably, many studies included in these analyses utilized conventional radiotherapy techniques. In contrast, IMRT has been increasingly adopted for esophageal cancer treatment owing to its superior precision and safety profile. In our study, which incorporated modern IMRT for all enrolled patients (n = 223), the incidence of treatment‐related adverse events did not differ significantly between groups. Notably, one NCRT patient died of intra‐abdominal bleeding within 90 days after surgery. This finding underscores the importance of developing effective strategies to mitigate the potential adverse effects of neoadjuvant therapy on surgical outcomes, which remains an important clinical priority and warrants further investigation. Notably, beyond the comparison of therapeutic strategies (NCRT versus ACRT), we identified BMI and cN status as independent prognostic factors for OS in resectable cT3‐4a ESCC patients. Previous studies investigating nutritional status and esophageal cancer prognosis have consistently demonstrated that a low pretreatment BMI is significantly correlated with poorer OS. 25 , 26 Similarly, cN+ disease has been widely established as a predictor of unfavorable prognosis across various treatment modalities for esophageal cancer. 27 , 28 Based on these three prognostic factors, we developed a well‐performing predictive model for OS in resectable cT3‐4a ESCC patients. Furthermore, we established a novel PS that integrated both BMI and cN status. Using this scoring system, patients were stratified into three risk categories: high‐ (3 points), intermediate‐ (2 points), and low‐risk (1 point). In the overall population and ACRT subgroup, patients in the highest risk category (PS 3) exhibited significantly worse OS than those in PS 1 and PS 2. However, among the patients receiving NCRT, no significant survival differences were observed across any risk groups. This finding suggests that NCRT may be applicable to a broader patient population and can significantly improve survival outcomes, even in high‐risk individuals. Although PSM was applied to enhance the comparability between treatment groups, this study has several limitations. First, its nonrandomized retrospective nature introduces an inherent risk of selection bias and potential underreporting of outcomes. Second, the single‐center design and limited sample size may restrict the generalizability of our findings. Most importantly, there is a critical need for large‐scale multicenter randomized controlled trials to directly compare the efficacy and safety of neoadjuvant and adjuvant chemoradiotherapy in this specific patient population. Therefore, further high‐quality evidence is essential to establish an optimal treatment strategy. CONCLUSION In conclusion, PSM analysis demonstrated that patients receiving NCRT had significantly superior OS compared with those treated with ACRT, while the PFS and safety profiles were comparable between the two approaches. Considering the limitations of the sample size and inherent heterogeneity of the study population, the generalizability of these findings requires further validation. Large‐scale prospective trials are necessary to identify the patient subgroups that may derive the greatest benefit from either neoadjuvant or adjuvant treatment strategies. AUTHOR CONTRIBUTIONS All authors have reviewed and approved the final manuscript. Their individual contributions were as follows: MQL curated data and wrote the original draft; YLY analyzed data and created visualizations; YBH conducted investigations and validation; JCL provided resources and project administration; and QWY and RZ conceived and supervised the study. CONFLICT OF INTEREST STATEMENT The authors declare no competing interests. ETHICAL APPROVAL Ethical approval for this retrospective study was obtained from the Ethics Committee of Fujian Cancer Hospital (No. K2022‐007‐01), and the requirement for informed consent was waived.